These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 10365927)

  • 1. Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases.
    Grundmann-Kollmann M; Korting HC; Behrens S; Kaskel P; Leiter U; Krähn G; Kerscher M; Peter RU
    J Am Acad Dermatol; 1999 Jun; 40(6 Pt 1):957-60. PubMed ID: 10365927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycophenolate mofetil in autoimmune and inflammatory skin disorders.
    Nousari HC; Sragovich A; Kimyai-Asadi A; Orlinsky D; Anhalt GJ
    J Am Acad Dermatol; 1999 Feb; 40(2 Pt 1):265-8. PubMed ID: 10025760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evaluation of the usefulness of mycophenolate mofetil in pemphigus.
    Powell AM; Albert S; Al Fares S; Harman KE; Setterfield J; Bhogal B; Black MM
    Br J Dermatol; 2003 Jul; 149(1):138-45. PubMed ID: 12890207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of refractory blistering autoimmune diseases with mycophenolic acid.
    Marzano AV; Dassoni F; Caputo R
    J Dermatolog Treat; 2006; 17(6):370-6. PubMed ID: 17853312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mycophenolate mofetil and enteric-coated mycophenolate sodium in the treatment of pemphigus vulgaris and pemphigus foliaceus.
    Doukaki S; Platamone A; Alaimo R; Bongiorno MR
    J Dermatolog Treat; 2015 Feb; 26(1):67-72. PubMed ID: 24521072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Red blood cell anemia in a patient with pemphigus vulgaris induced by the use of mycophenolate mofetil and prednisone.
    Scheinfeld N
    J Dermatolog Treat; 2007; 18(4):243-5. PubMed ID: 17671884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of pemphigus vulgaris with mycophenolate mofetil as a steroid-sparing agent.
    Esmaili N; Chams-Davatchi C; Valikhani M; Farshidfar F; Parvaneh N; Tamizifar B
    Eur J Dermatol; 2008; 18(2):159-64. PubMed ID: 18424375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycophenolate mofetil as adjuvant in pemphigus vulgaris.
    Sarma N; Ghosh S
    Indian J Dermatol Venereol Leprol; 2007; 73(5):348-50. PubMed ID: 17921620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment with mycophenolate mofetil of four Japanese patients with pemphigus vulgaris.
    Koga H; Ishii N; Hamada T; Karashima T; Nakama T; Yasumoto S; Hashimoto T
    Eur J Dermatol; 2010; 20(4):472-5. PubMed ID: 20406724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pediatric pemphigus vulgaris: durable treatment responses achieved with prednisone and mycophenolate mofetil (MMF).
    Baratta A; Camarillo D; Papa C; Treat JR; Payne AS; Rozenber SS; Yan AC
    Pediatr Dermatol; 2013; 30(2):240-4. PubMed ID: 22747679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Where does rituximab fit in the treatment of autoimmune mucocutaneous blistering skin disease?
    Nigam R; Levitt J
    J Drugs Dermatol; 2012 May; 11(5):622-5. PubMed ID: 22527431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial.
    Beissert S; Mimouni D; Kanwar AJ; Solomons N; Kalia V; Anhalt GJ
    J Invest Dermatol; 2010 Aug; 130(8):2041-8. PubMed ID: 20410913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic evaluation of mycophenolate mofetil for pemphigus.
    Doukaki S; Pistone G; Aricò M; Bongiorno MR
    Expert Opin Drug Metab Toxicol; 2011 Feb; 7(2):237-44. PubMed ID: 21192770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy.
    Inductivo-Yu I; Adams A; Gish RG; Wakil A; Bzowej NH; Frederick RT; Bonacini M
    Clin Gastroenterol Hepatol; 2007 Jul; 5(7):799-802. PubMed ID: 17509945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycophenolate mofetil monotherapy for pemphigus vulgaris.
    Bredlich RO; Grundmann-Kollmann M; Behrens S; Kerscher M; Peter RU
    Br J Dermatol; 1999 Nov; 141(5):934. PubMed ID: 10583186
    [No Abstract]   [Full Text] [Related]  

  • 16. Mycophenolate mofetil for the management of autoimmune bullous diseases.
    Eskin-Schwartz M; David M; Mimouni D
    Dermatol Clin; 2011 Oct; 29(4):555-9. PubMed ID: 21924997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris.
    Olszewska M; Kolacinska-Strasz Z; Sulej J; Labecka H; Cwikla J; Natorska U; Blaszczyk M
    Am J Clin Dermatol; 2007; 8(2):85-92. PubMed ID: 17428113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycophenolate mofetil as a first-line steroid-sparing agent in the treatment of pemphigus vulgaris.
    Vyas N; Patel NS; Cohen GF
    J Drugs Dermatol; 2013 Feb; 12(2):210-6. PubMed ID: 23377396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycophenolate mofetil as an adjuvant therapy for classic and endemic pemphigus foliaceus.
    Kawashita MY; Tsai K; Aoki V; Santi CG; Maruta CW; Rivitti E
    J Dermatol; 2005 Jul; 32(7):574-80. PubMed ID: 16335874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment outcomes in a cohort of patients with mucosal-predominant pemphigus vulgaris.
    Ojaimi S; O'Connor K; Lin MW; Schifter M; Fulcher DA
    Intern Med J; 2015 Mar; 45(3):284-92. PubMed ID: 25534017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.